Arbutus Biopharma (ABUS) Operating Income: 2009-2025
Historic Operating Income for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to -$8.7 million.
- Arbutus Biopharma's Operating Income rose 59.61% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.8 million, marking a year-over-year increase of 43.70%. This contributed to the annual value of -$76.3 million for FY2024, which is 2.28% up from last year.
- Arbutus Biopharma's Operating Income amounted to -$8.7 million in Q3 2025, which was down 681.92% from $1.5 million recorded in Q2 2025.
- In the past 5 years, Arbutus Biopharma's Operating Income ranged from a high of $1.5 million in Q2 2025 and a low of -$25.7 million during Q1 2025.
- In the last 3 years, Arbutus Biopharma's Operating Income had a median value of -$19.4 million in 2024 and averaged -$17.0 million.
- In the last 5 years, Arbutus Biopharma's Operating Income tumbled by 58.68% in 2023 and then skyrocketed by 106.89% in 2025.
- Quarterly analysis of 5 years shows Arbutus Biopharma's Operating Income stood at -$20.8 million in 2021, then dropped by 8.49% to -$22.6 million in 2022, then grew by 8.04% to -$20.7 million in 2023, then surged by 32.84% to -$13.9 million in 2024, then skyrocketed by 59.61% to -$8.7 million in 2025.
- Its Operating Income stands at -$8.7 million for Q3 2025, versus $1.5 million for Q2 2025 and -$25.7 million for Q1 2025.